UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I ...

Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2024 Results Company to Host Conference Call on Tuesday, May 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___ to ___ . Commission file number: 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2023 Results Company to Host Conference Call on Tuesday, Feb. 27, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2024 /PRNewswire/ -- Astrana Health, Inc. (together with its subsidiaries and affiliated entities, "Astrana") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financi ...

Revenue Performance - For the three months ended September 30, 2023, total revenue was $348.2 million, a 10% increase from $317.0 million in the same period of 2022, primarily driven by a $78.1 million increase in capitation revenue [238]. - For the nine months ended September 30, 2023, total revenue reached $1,033.6 million, reflecting a 22% increase from $850.0 million in the same period of 2022, with capitation revenue increasing by $229.2 million [240]. - Revenue for the three months ended September 30, 2023, was $326.5 million, an increase of $32.9 million, or 11%, compared to the same period in 2022 [268]. - Revenue for the nine months ended September 30, 2023, was $966.4 million, an increase of $184.2 million, or 24%, compared to the same period in 2022 [269]. - Revenue for the three months ended September 30, 2023, was $36.9 million, an increase of 22% compared to $30.3 million for the same period in 2022 [273]. - Revenue for the nine months ended September 30, 2023, was $102.5 million, reflecting a 15% increase from $89.3 million in the same period of 2022 [274]. Operating Performance - Operating expenses for the three months ended September 30, 2023, totaled $309.1 million, a 16% increase from $266.9 million in the same period of 2022 [233]. - Operating income for the three months ended September 30, 2023, was $40.3 million, a decrease of $6.0 million, or 13%, compared to the same period in 2022 [268]. - Operating income for the nine months ended September 30, 2023, was $90.5 million, an increase of $18.8 million, or 26%, compared to the same period in 2022 [269]. - Operating income for the three months ended September 30, 2023, was $6.4 million, up 27% from $5.1 million in the prior year [273]. - Operating income for the nine months ended September 30, 2023, decreased to $19.8 million, down 17% from $23.8 million in the previous year [274]. Net Income - Net income for the three months ended September 30, 2023, was $27.973 million, a 17% increase from $23.897 million in the same period of 2022 [233]. - Net income attributable to Apollo Medical Holdings, Inc. for the three months ended September 30, 2023, was $22.1 million, a decrease of $1.1 million compared to the same period in 2022 [264]. - The net income guidance for 2023 is set between $59.5 million and $71.5 million [276]. Cash Flow and Investments - Cash, cash equivalents, and investments totaled $277.0 million as of September 30, 2023, down from $293.6 million at the end of 2022 [283]. - Cash provided by operating activities for the nine months ended September 30, 2023, was $48.9 million, compared to cash used in operating activities of $2.8 million in the same period of 2022 [287]. - Cash used in investing activities for the nine months ended September 30, 2023, was $54.1 million, significantly higher than $20.3 million in the prior year, representing a 166% increase [286]. - Cash used in financing activities for the nine months ended September 30, 2023, was $8.6 million, a significant decrease from $26.0 million in the same period of 2022 [289]. Debt and Financing - The company entered into a Credit Agreement Amendment on November 3, 2023, increasing its credit facility to $700.0 million, including a new term loan of up to $300.0 million [223]. - The Amended Credit Agreement provides a total facility of $700.0 million, including a $400.0 million revolving credit facility and a new term loan of up to $300.0 million [296]. - As of September 30, 2023, the Company had $180.0 million in outstanding borrowings under the Amended Credit Agreement, with interest rates ranging from 1.25% to 2.50% based on leverage ratio [305]. - Future debt commitments include $181.2 million due in 2026, which represents the largest single-year obligation [295]. - A hypothetical 1% change in interest rates would have impacted the interest expense by $2.1 million for the three months ended September 30, 2023 [305]. Acquisitions and Partnerships - The company announced the acquisition of assets related to Community Family Care Medical Group, managing healthcare for over 200,000 members in Los Angeles [225]. - A partnership was established with Associated Hispanic Physicians, which includes over 150 primary care providers and 450 specialists, expected to onboard by March 2024 [226]. Other Financial Metrics - General and administrative expenses for the three months ended September 30, 2023, were $29.4 million, an increase of $8.0 million, or 38%, compared to the same period in 2022 [244]. - Interest expense for the three months ended September 30, 2023, was $3.8 million, an increase of $1.4 million, due to higher interest rates [252]. - Interest income for the three months ended September 30, 2023, was $3.3 million, compared to $0.2 million for the same period in 2022 [254]. - Unrealized loss for the three months ended September 30, 2023, was $0.3 million, a decrease of $6.4 million compared to the same period in 2022 [256]. - Other income for the three months ended September 30, 2023, was $1.9 million, an increase of $3.2 million compared to a loss of $1.3 million for the same period in 2022 [258]. Patient Management - The company managed approximately 0.9 million patients as of September 30, 2023, down from 1.2 million in the same period of 2022 [235]. Excluded Assets - Total Excluded Assets as of September 30, 2023, amounted to $124.8 million, slightly down from $127.9 million as of December 31, 2022 [292]. - Excluded Assets net loss for the nine months ended September 30, 2023, was $5.0 million, an improvement compared to a loss of $16.0 million in the same period of 2022 [292]. - Cash and cash equivalents in Excluded Assets decreased to $11.6 million as of September 30, 2023, from $30.2 million at the end of 2022 [292]. - Total operating expenses for Excluded Assets increased to $3.3 million for the nine months ended September 30, 2023, compared to $2.9 million in the prior year [292].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I.R.S. Employer Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdict ...

Company Overview - Apollo Medical Holdings, Inc. coordinates care for approximately 1.3 million patients as of December 31, 2022, through a network of over 11,000 contracted healthcare providers[28]. - The company operates under the Global and Professional Direct Contracting Model (GPDC Model) and has transitioned to the ACO REACH Model as of January 1, 2023[27]. - ApolloMed's management service organizations (MSOs) provide administrative support to affiliated physician groups, enhancing operational efficiency[26]. - Following the 2017 merger with NMM, ApolloMed has positioned itself as a significant player in the healthcare delivery segment, leveraging NMM's assets and revenues[24]. - ApolloMed's common stock is listed on the NASDAQ Capital Market under the symbol "AMEH"[26]. Revenue Model - Revenue streams include capitation payments from CMS, risk pool settlements, management fees, and fee-for-service reimbursements, indicating a diversified revenue model[25]. - ApolloMed's financial performance is influenced by the capitation model, where fixed payments are received from health plans in exchange for healthcare service delivery[32]. - The company has diversified its service offerings, reducing business risk and increasing revenue opportunities across a horizontally integrated care network[81]. - The company received $48.8 million and $21.8 million in risk pool savings related to the 2021 and 2020 performance years, respectively[77]. - For the years ended December 31, 2022, 2021, and 2020, four payors accounted for 59.0%, 49.6%, and 53.4% of total net revenue, respectively[79]. Healthcare Trends - U.S. healthcare expenditures are projected to grow at an average annual rate of 5.1% from 2021 to 2030, reaching approximately $6.8 trillion by 2030[43]. - Medicare spending increased by 8.4% to $900.8 billion in 2021, while Medicaid spending rose by 9.2% to $734.0 billion[43]. - The healthcare share of U.S. GDP is expected to remain consistent at 19.6% by 2030, down from 19.7% in 2020[43]. - The healthcare industry is shifting towards value-based payment models, with an increasing number of Americans covered by capitated payment programs[46]. Strategic Focus - The company emphasizes a value-based healthcare approach, focusing on patient satisfaction and cost efficiency in its service delivery[23]. - ApolloMed's strategic focus includes expanding its integrated healthcare models to enhance care coordination and improve patient outcomes[25]. - The integrated medical systems are positioned to leverage scale and expertise to improve care quality and lower costs[51]. - Population health management is a central trend within healthcare delivery, aiming to improve health outcomes while lowering costs[56]. Regulatory Compliance - The company is subject to corporate practice of medicine laws in California, which restrict non-physician ownership in medical practices[30]. - Regulatory compliance is critical, as violations of healthcare laws could have a material adverse effect on the company's business and financial condition[94]. - The company must navigate complex anti-kickback statutes, which prohibit remuneration for patient referrals, with violations leading to severe penalties[103]. - Compliance with HIPAA regulations is critical, as violations may result in civil and criminal penalties, including fines and mandatory notifications[116]. Competition - The company faces significant competition from larger healthcare management companies and provider networks, which have greater financial and personnel resources[88]. - In the greater Los Angeles area, competitors include Regal Medical Group, Lakeside Medical Group, and Optum, which are part of larger healthcare networks[89]. - The company faces competition in the creation and management of Accountable Care Organizations (ACOs) from larger groups like Privia Health and Aledade[90]. Employee Engagement - As of December 31, 2022, ApolloMed had 1,362 employees, with no labor union membership and no work stoppages reported[128]. - The company emphasizes employee engagement and retention through ongoing surveys and programs aimed at enhancing satisfaction and productivity[129]. Management and Expertise - The management team has extensive experience in managing healthcare organizations, providing a strong foundation for future growth[82]. - The company has developed expertise in population health management, resulting in improved Risk Adjustment Factor (RAF) scores and higher payments from health plans[87]. - The healthcare management programs have led to improved quality metrics in both inpatient and outpatient settings, enhancing patient satisfaction and CMS scores[87].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdicti ...